News
ZLAB
25.90
-0.50%
-0.13
Morgan Stanley Sticks to Its Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 3d ago
Citic Securities Sticks to Its Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 3d ago
Weekly Report: what happened at ZLAB last week (0803-0807)?
Weekly Report · 5d ago
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
TipRanks · 6d ago
Citi Sticks to Their Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 08/08 00:26
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
TipRanks · 08/08 00:25
Zai Lab Price Target Raised to $45.00/Share From $44.00 by Citigroup
Dow Jones · 08/07 20:22
Zai Lab Is Maintained at Buy by Citigroup
Dow Jones · 08/07 20:22
Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45
Benzinga · 08/07 20:12
Zai Lab price target raised to $45 from $44 at Citi
TipRanks · 08/07 10:51
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
NASDAQ · 08/06 14:30
Zai Lab reports Q2 EPS (46c), consensus (68c)
TipRanks · 08/06 11:00
Zai Lab reports Q2 results
Seeking Alpha · 08/06 10:44
Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate
Benzinga · 08/06 10:32
Zai Lab's Revenue Trajectory Keeps Bending in the Wrong Direction—Or Does It
Barchart · 08/05 16:36
Zai Lab receives Orphan Drug status for ADC for neuroendocrine carcinomas
Seeking Alpha · 08/03 13:28
Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas
Benzinga · 08/03 11:27
Weekly Report: what happened at ZLAB last week (0727-0731)?
Weekly Report · 08/03 09:42
Zai Lab treatment of neuroendocrine carcinoma granted FDA orphan designation
TipRanks · 07/30 11:02
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
TipRanks · 07/29 00:36
More
Webull provides a variety of real-time ZLAB stock news. You can receive the latest news about Zai Lab Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.